Patents by Inventor Marc Labroli

Marc Labroli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES
    Publication number: 20240083910
    Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 14, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Richard Thaddeus Berger, JR., Christopher Douglas Cox, Brendan M. Crowley, Marc Labroli, Michael Aaron Plotkin, Izzat Tiedje Raheem, Deyou Sha, Anthony W. Shaw, Jason W. Skudlarek, Ling Tong
  • AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES
    Publication number: 20240067657
    Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R7, and R8 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compound, and methods of using the Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 29, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kira A. Armacost, Richard Thaddeus Berger, Jr., Andrew J. Cooke, Christopher Douglas Cox, Brendan M. Crowley, Marc Labroli, Michael Aaron Plotkin, Izzat Tiedje Raheem, Anthony W. Shaw, Kelly-Ann S. Schlegel, Jason W. Skudlarek, Ling Tong
  • FUSED BICYCLIC PYRAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES
    Publication number: 20240059693
    Abstract: The present invention relates to novel Fused Bicyclic Pyrazole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are as defined herein. The present invention also relates to compositions comprising at least one Fused Bicyclic Pyrazole Derivative, and methods of using the Fused Bicyclic Pyrazole Derivatives for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 14, 2021
    Publication date: February 22, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ronald K. Chang, Andrew J. Cooke, JR., Christopher Douglas Cox, Marc Labroli, Izzat Tiedje Raheem, Jack D. Scott, Jeffrey W. Schubert, Jason W. Skudlarek, Zheng Tan, Ling Tong
  • Tricyclic heterocycle compounds useful as HIV integrase inhibitors
    Patent number: 11413292
    Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, Z, R1 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: August 16, 2022
    Assignee: Merck, Sharp & Dohme LLC
    Inventors: Mark W. Embrey, Timothy John Hartingh, Marc Labroli, Izzat T. Raheem
  • TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
    Publication number: 20210361662
    Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, Z, R1 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: February 11, 2019
    Publication date: November 25, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mark W. Embrey, Timothy John Hartingh, Marc Labroli, Izzat T. Raheem
  • Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
    Patent number: 8586576
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: November 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Kartik M. Keertikar
  • TRIAZOLOPYRAZINONES AS P2X7 RECEPTOR ANTAGONISTS
    Publication number: 20130196986
    Abstract: The invention provides certain 3,7-disubstituted-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-ones of the Formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R8, and X are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating pain or an inflammatory disease.
    Type: Application
    Filed: September 16, 2011
    Publication date: August 1, 2013
    Inventors: Marc Labroli, Michael F. Czarniecki, Cory Seth Poker
  • Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
    Patent number: 7605155
    Abstract: In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: October 20, 2009
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Kartik M. Keertikar
  • Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
    Publication number: 20070281951
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or compositions.
    Type: Application
    Filed: April 20, 2007
    Publication date: December 6, 2007
    Inventors: Timothy Guzi, Kamil Paruch, Michael Dwyer, Marc Labroli, Kartik Keertikar
  • Pyrazolopyrimidines as cyclin dependent kinase inhibitors
    Publication number: 20070225270
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: February 23, 2007
    Publication date: September 27, 2007
    Inventors: Timothy Guzi, Kamil Paruch, Michael Dwyer, Marc Labroli, Kartik Keertikar
  • Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
    Publication number: 20070072881
    Abstract: In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: October 4, 2006
    Publication date: March 29, 2007
    Inventors: Timothy Guzi, Kamil Paruch, Michael Dwyer, Marc Labroli, Kartik Keertikar
  • Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
    Patent number: 7196078
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: March 27, 2007
    Assignee: Schering Corpoartion
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Kartik M. Keertikar
  • Compounds for inhibiting KSP Kinesin activity
    Publication number: 20060281778
    Abstract: The present invention provides compounds of Formula I (wherein R1, R3, X, W, Z and ring Y are as defined herein). The present invention also provides compositions comprising these compounds that are useful for treating cellular proliferative diseases or disorders associated with KSP kinesin activity and for inhibiting KSP kinesin activity.
    Type: Application
    Filed: March 7, 2006
    Publication date: December 14, 2006
    Inventors: Jayaram Tagat, Timothy Guzi, Marc Labroli, Cory Poker, Angela Kerekes, Tao Yu, Hon-Chung Tsui, Neng-Yang Shih, Yushi Xiao, Sunil Paliwal
  • Compounds for inhibiting KSP kinesin activity
    Publication number: 20060247320
    Abstract: The present invention provides compounds of Formula I (wherein R1, R3, X, W, Z and ring Y are as defined herein). The present invention also provides compositions comprising these compounds that are useful for treating cellular proliferative diseases or disorders associated with KSP kinesin activity and for inhibiting KSP kinesin activity.
    Type: Application
    Filed: March 7, 2006
    Publication date: November 2, 2006
    Inventors: Jayaram Tagat, Timothy Guzi, Marc Labroli, Cory Poker, Yushi Xiao, Angela Kerekes, Tao Yu, Sunil Paliwal, Hon-Chung Tsui, Neng-Yang Shih, Stuart McCombie, Vincent Madison, Charles Lesburg, Jose Duca
  • Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
    Publication number: 20060128725
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: October 6, 2005
    Publication date: June 15, 2006
    Inventors: Timothy Guzi, Kamil Paruch, Michael Dwyer, Marc Labroli, Kartik Keertikar